TSE:FRXFennec Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$11.44 +0.25 (+2.23 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's RangeC$11.43Now: C$11.44▼C$11.4450-Day RangeC$9.95MA: C$11.18▼C$12.7052-Week RangeC$5.00Now: C$11.44▼C$13.24Volume205 shsAverage Volume1,422 shsMarket CapitalizationC$290.07 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Fennec Pharmaceuticals. Previous Next 2.6 Community Rank Outperform VotesFennec Pharmaceuticals has received 95 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFennec Pharmaceuticals has received 88 “underperform” votes. (Add your “underperform” vote.)Community SentimentFennec Pharmaceuticals has received 51.91% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote “Outperform” if you believe FRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFennec Pharmaceuticals does not currently pay a dividend.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Fennec Pharmaceuticals is -16.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fennec Pharmaceuticals is -16.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFennec Pharmaceuticals has a P/B Ratio of 26.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:FRX Previous Symbol CUSIPN/A CIKN/A Webfennecpharma.com Phone+1-919-6364530Debt Debt-to-Equity RatioN/A Current Ratio5.31 Quick Ratio5.19Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.36 per share Price / Cash Flow31.97 Book ValueC$0.43 per share Price / Book26.92Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees3 Outstanding Shares25,356,000Market CapC$290.07 million Next Earnings Date8/14/2020 (Estimated) OptionableNot Optionable TSX:FRX Rates by TradingView Receive FRX News and Ratings via Email Sign-up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter. Fennec Pharmaceuticals (TSE:FRX) Frequently Asked Questions How has Fennec Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Fennec Pharmaceuticals' stock was trading at C$9.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FRX stock has increased by 26.8% and is now trading at C$11.44. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Fennec Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fennec Pharmaceuticals. When is Fennec Pharmaceuticals' next earnings date? Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Fennec Pharmaceuticals. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (TSE:FRX) issued its quarterly earnings data on Thursday, May, 14th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.26). View Fennec Pharmaceuticals' earnings history. Has Fennec Pharmaceuticals been receiving favorable news coverage? Headlines about FRX stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Fennec Pharmaceuticals earned a news impact score of 1.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Fennec Pharmaceuticals. Who are some of Fennec Pharmaceuticals' key competitors? Some companies that are related to Fennec Pharmaceuticals include Trillium Therapeutics (TRIL), BELLUS Health (BLU), PureTech Health (PRTC), Bellus Health (BLU), Aptose Biosciences (APS), Oxford BioMedica (OXB), CEL-SCI (CVM), Cel-Sci (CVM), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), Silence Therapeutics (SLN), Neptune Wellness Solutions (NEPT), TELIX Pharmaceutical (TLX) and Starpharma (SPL). View all competitors. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Encanto Potash (EPO), Acadian Timber (ADN), Alaris Royalty (AD), Agellan Commercial Real Estate Invtmt TR (ACR.UN), AutoCanada (ACQ), ATCO LTD -CLASS I Common Stock (US funds) (ACO.X), Accord Financial (ACD), Aurora Cannabis (ACB), Air Canada (AC) and Barrick Gold (ABX). Who are Fennec Pharmaceuticals' key executives? Fennec Pharmaceuticals' management team includes the following people: Mr. Rostislav Raykov, CEO & Director (Age 43)Mr. Robert C. Andrade, Chief Financial Officer (Age 44)Mr. Mark Gowland, ControllerMr. Lei Fang, Pres of Pharstat IncMs. Anne McKay, Regulatory Consultant (Age 65) What is Fennec Pharmaceuticals' stock symbol? Fennec Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "FRX." How do I buy shares of Fennec Pharmaceuticals? Shares of FRX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Fennec Pharmaceuticals' stock price today? One share of FRX stock can currently be purchased for approximately C$11.44. How big of a company is Fennec Pharmaceuticals? Fennec Pharmaceuticals has a market capitalization of C$290.07 million. Fennec Pharmaceuticals employs 3 workers across the globe. What is Fennec Pharmaceuticals' official website? The official website for Fennec Pharmaceuticals is fennecpharma.com. How can I contact Fennec Pharmaceuticals? Fennec Pharmaceuticals' mailing address is 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States. The biopharmaceutical company can be reached via phone at +1-919-6364530. This page was last updated on 7/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
